Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Villa A, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Lombardi AV, Sorio R, Mangili G, Priolo D, Magni G, Morabito A. Pignata S, et al. Among authors: sorio r. BMC Cancer. 2008 Sep 1;8:252. doi: 10.1186/1471-2407-8-252. BMC Cancer. 2008. PMID: 18761742 Free PMC article.
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Pignata S, et al. Among authors: sorio r. BMC Cancer. 2006 Aug 1;6:202. doi: 10.1186/1471-2407-6-202. BMC Cancer. 2006. PMID: 16882344 Free PMC article. Clinical Trial.
Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer.
Nicoletto MO, Tumolo S, Sorio R, Cima G, Endrizzi L, Nascimben O, Vinante O, Artioli G, Donach M, Cartei G; Goccne Group (Gruppo Oncologico Cooperativo Clinico Nord-est), Padua, Italy. Nicoletto MO, et al. Among authors: sorio r. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):986-92. doi: 10.1111/j.1525-1438.2007.00862.x. Epub 2007 Feb 19. Int J Gynecol Cancer. 2007. PMID: 17316364 Clinical Trial.
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G; SOCRATES and MITO investigators. Pignata S, et al. Among authors: sorio r. Oncology. 2006;71(5-6):320-6. doi: 10.1159/000108592. Epub 2007 Sep 18. Oncology. 2006. PMID: 17878745
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F. Pignata S, et al. Among authors: sorio r. Oncology. 2009;76(1):49-54. doi: 10.1159/000178760. Epub 2008 Nov 27. Oncology. 2009. PMID: 19039248 Clinical Trial.
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A. Pignata S, et al. Among authors: sorio r. Crit Rev Oncol Hematol. 2009 Sep;71(3):233-41. doi: 10.1016/j.critrevonc.2008.12.010. Epub 2009 Jan 28. Crit Rev Oncol Hematol. 2009. PMID: 19179095
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
Pisano C, Morabito A, Sorio R, Breda E, Lauria R, Gebbia V, Scaltriti L, Scalone S, Zagonel V, Greggi S, Beneduce G, Losito S, Gallo C, Di Maio M, Forestieri V, Pignata S. Pisano C, et al. Among authors: sorio r. Cancer Chemother Pharmacol. 2009 Oct;64(5):1021-7. doi: 10.1007/s00280-009-0958-0. Epub 2009 Mar 6. Cancer Chemother Pharmacol. 2009. PMID: 19266200 Clinical Trial.
Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Sorio R, Rabaiotti E, Scambia G, Cormio G, Scarampi L, Greggi S, Savarese A, Marinaccio M, Scollo P, Pignata S. Magazzino F, et al. Among authors: sorio r. Int J Gynecol Cancer. 2011 Aug;21(6):1063-70. doi: 10.1097/IGC.0b013e318218f270. Int J Gynecol Cancer. 2011. PMID: 21633300
145 results